

# Index

An “f” or “t” suffix indicates that the term may be found in a figure or table on the page indicated.

- Abacavir sulfate, 333
- Accessory genes, *see also specific genes*
  - HIV-1, 239–267; *see also* HIV-1 accessory genes
  - nucleic acid vaccination against HIV-1, 197–198
- Acell gene gun, 120
- Acquired Immune Deficiency Syndrome: *see* AIDS (Acquired Immune Deficiency Syndrome)
- ADCC: *see* Antibody-dependent cellular cytotoxicity (ADCC)
- Adefovir dipivoxil, 337
- Adeno-associated viruses, 313
- Adhesion molecules and HTLV infection, 95–103
  - gel immunoprecipitation, 100f
  - ICAM-1, 98, 102
  - ICAM-2, 102
  - ICAM-3, 96–99, 100–101f, 102
  - syncytium inhibition with mAbs to cell surface antigens, 99f
  - three possible roles, 103f
- Adult T cell leukemia, 87
- Agadjanyan, Michael G., 87–107
- AIDS (Acquired Immune Deficiency Syndrome), *see also* HIV (human immunodeficiency virus)
  - clinical application of drugs, results, 307–308
  - AIDS (Acquired Immune Deficiency Syndrome) (*cont.*)
    - immune dysfunction associated with anti-CD3 monoclonal antibodies, 33
    - DP IV (CD26) blockage, 33
    - HIV-1 gp41, effects of, 41–44
    - HIV-1 gp120, effects on immune cell function, 35–41
    - HIV-1 *nef*, 44–53
    - HIV-1 Tat, effect on immune cell function, 31–35, 53
    - immune dysfunction associated with, 29–60
      - molecular changes, 62
  - AIDS Clinical Trial Group (ACTG), 325, 332
  - ALX40–4C, 278
  - AMD3100, 277–278
  - American Academy of Pediatrics, 338
  - American College of Obstetricians and Gynecologists, 338
  - Amphotropic murine leukemia virus (MLV), 314–315
  - Animal models, vaccine development
    - nonhuman primate models, 115–116
    - rodent models, 113–115
  - Animal vaccine challenge studies, 125–129, 130
    - nonhuman primate vaccine studies, 129
    - rabbit vaccine studies, 126–128
    - rat vaccine studies, 125–126

- Anti-alpha-galactosyl, 67
- Antibody-dependent cell-mediated (ADCM) cytotoxicity, 218
- Antibody-dependent cellular cytotoxicity (ADCC), 145, 148t, 151–153
- Anti-CD3 monoclonal antibodies, 33
- Antiretroviral therapy, pediatric HIV: *see* Pediatric HIV
- Antisense RNAs, 308–310
- Antiviral agents, gene delivery, 312–316
- AOP-RANTES, 275
- Apoptosis
  - HIV-1 gp120, effects of, 38
  - Tat induced, 34–35
- Arp, J., 109–142
- Arthropathy, HTLV-I associated, 22
- ATL (adult T cell leukemia), 87
- ATLL, 109–110
- Autoimmune diseases, HTLV-associated, 22–23
- Avian leukosis virus (ALV), 315
- Ayyavoo, Velpandi, 239–267
- Azidothymidine, 331
- Bacille Calmette–Guerin (BCG), 180
- B cell epitopes and linear sites, 146–147t, 149–151
- Bennett, Mosi K., 87–107
- Bjorling, Ewa, 143–163
- BOB receptors, 148
- Bordetella*, 63
- Bovine leukemia virus (BLV), 113
- Boyer, Jean D., 191–215
- Branhamella*, 63
- Bristow, Cynthia L., 1–16
- Bronchus-associated lymphoreticular tissue (BALT), 6
- Campylobacter jejuni*, 63
- Candida albicans*, 66
- Carbohydrate interactions and HIV-1, 61–85
  - amino acid residues, 69
  - anti-alpha-galactosyl, 67
  - bacterial lipooligosaccharides that mimic host glycosphingolipids, 65f
  - bordetella*, 63
  - branhamella*, 63
  - campylobacter jejuni*, 63
  - carbohydrate moieties, influence on immunogenicity of HIV, 67–72
- Carbohydrate interactions and HIV-1 (cont.)
  - continuous antibody epitopes, exposure on gp120, 68f
  - glycans, role on V3, 69–71
  - glycoconjugate forms, 63
  - glycosylation, 61–63
  - gp260, glycans of, 68–69, 73–74
  - haemophilus*, 63
  - helicobacter pylori*, 63, 65
  - IgA, 78–79
  - LeYis, 66–67
  - LOS mimicking structures of
    - glycosphingolipids (GSLs), 64–65
  - mucosal immune responses, 78–79
  - neisseria*, 63, 65
  - neutralization sites, glycosylation and, 71–72
  - N-glycan localized within V3 loop, influence, 69–70
  - schematic representation of general organization of high-MW LPs, low MW LPS, and LOS, 64f
  - ubiquitous nature of carbohydrate structure, 63–67
  - vaccine development and, 62–63, 72–77
    - peptide motifs that mimic carbohydrate structures, 761
    - planar-X–planar sequence motif, 76
    - T lymphotropic virus type I, 72–73
- Cardiomyopathy, 331
- CARIYYRYDGTAY, 75
- CCR1, 148
- CCR2b, 148
- CCR3, 148, 274
- CCR5, 93, 148, 272–273, 274–276
- CCR8, 274
- CD4
  - binding of HIV-1, 150
  - discovery of, 270
  - gene therapy and HIV-1 infection, 312
  - nef* gene, interaction, 251
  - nucleic acid vaccination against HIV-1, 203–204
- CD4+ T cells
  - immune responses against HIV-2, 145
  - vaccine development and, 93–94, 111
- CD4+ T lymphocytes, 7, 9, 308
  - early concepts, 29
- CD8+ cells, 155–156
- CD34+ cells, 40–41
- Cell-mediated HIV-2 immunity, 153–156

- Chemokine receptors, 29–30  
 antiviral receptors designed to prevent use  
 of for entry by HIV-1, 269–285  
 HIV-1 coreceptors, as, 270–272  
 inhibition of HIV-1, 273–274  
 pathogenic determinants, as, 272–273  
 small-molecule inhibitors of, 276–279  
 therapeutics directed at, 274–276
- Children: *see* Pediatric HIV
- Chimeric simian/immunodeficiency virus  
 (SHIV)  
 Convergent/synergistic passive  
 immunotherapy, 222  
 mucosal vaccine development and, 166–  
 167, 176
- Cholera toxin, 181
- Chronic fatigue syndrome, association with  
 HTLV, 24
- Chronic lymphocytic leukemia, 2 1
- Cianciolo, George J., 29–60
- Codon optimization, 205–206
- Convergent/synergistic passive  
 immunotherapy, 222–223
- Costimulatory molecules, 39
- Cotropia, Joseph P., 217–238
- CpG motifs, 205
- CRE-binding protein (CREB), 90
- CRE-modulator protein (CREM), 90
- Crixovan, 341
- CS-3, 41–42
- CSGKLC, 223
- CTL: *see* Cytotoxic T lymphocytes (CTL)
- Cutaneous T-cell lymphoma (CTCL), 21
- CXCR4, 93,273,274, 276–278, 316
- Cytokines  
 HIV-1 gp120, effects of, 39  
 HIV-1 *nef* and, 48–49  
 nucleic acid vaccination against HIV-1,  
 203–204
- Cytotoxic natural killer cells, 156
- Cytotoxic T lymphocytes (CTL), 153–155  
 HIV mucosal vaccines and, 168, 174, 177  
 nonhuman primates, 170  
 nucleic acid vaccination against HIV-1,  
 195  
 peptide epitopes, 153t
- Dekaban, G. A., 109–142
- De La Morena, Maite, 325–356
- Delavirdine, 335
- Dermatitis, childhood, 23
- Dermatologic disease, association with  
 HTLV, 23–24
- Dideoxyinosine (Didanosine), 331–332
- Diphtheria vaccination, 191
- Diplyridodiazepinone, 334
- DNA decoys, 310
- DNA gene transfer, immunization by, 119–120
- DNA vaccines, 180  
*gag/pol* genes, 241–242  
 nucleic acid vaccination against HIV 1,  
 197f, 199–200, 209t
- Doms, Robert W., 269–285
- Doranz, Benjamin J., 269–285
- Dornburg, Ralph, 307–323
- DP IV (CD26) blockage, 33
- Ecotropic murine leukemia virus (MLV), 315
- Efavirenz, 334–335
- ELISA: *see* Enzyme-linked immunosorbent  
 assay (ELISA)
- Emmanuel, Patricia J., 325–356
- Envelope glycoproteins, 122–123  
 cell epitotype located in, 146–147t
- Envelope gp46, 120
- Envelope gp125, 144, 150–151
- Envelope gp136, 144
- Envelope protein gp160, 196
- Enzyme-linked immunosorbent assay  
 (ELISA), 40, 76
- Escherichia coli*, 116, 129
- Feline immunodeficiency virus (FIV), 21 7
- Food and Drug Administration, 241
- Franchini, G., 109–142
- Gag*, 123–124,145
- Gag/pol* genes, 198,209–210  
 DNA vaccines targeting, 241–242
- Gallo, Robert, 88
- Gel immunoprecipitation, 100f
- Gene therapy and HIV-1 infection, 307–323  
 antisense RNAs, 308–310  
 antiviral agents, gene delivery, 312–316  
 CD4 as decoy, 3 12  
 conventional pharmaceutical agents, 307–308  
 DNA decoys, 310  
 human leukocyte antigen (HLA), 312  
 ribozymes, 308–310  
 single-chain antibodies, 312  
 toxic genes, 311–312  
 transdominant mutant proteins, 310–31 1

- Genetic antivirals, 308  
 Genotypic resistance in protease, 297  
 Gentile, Teresa C., 17–28  
 Glycans, role on V3, 69–71  
 Glycosylation, 61–63  
   vaccine development, 122  
 Goodenow, Maureen M., 287–305  
 Gp41: *see* HIV-1 gp41, effects on immune cell function  
 Gp120: *see* HIV-1 gp120, effects on immune cell function  
 Gp125, 144, 149–151  
 Gp260, glycans of, 68–69, 73–74  
 Graves' disease, 23
- Haemophilus*, 63  
*Haemophilus influenzae*, 63  
 Hairy cell leukemia, 18, 21  
 HAM (HTLV-I associated myelopathy), 87  
 HAM/TSP, 18–20  
   age of onset, 18–19  
   immigrants, occurrence, 110  
   Sjogren's syndrome and, 22  
   tax proteins, 121  
 Heat-labile enterotoxin (LT), 181  
*Helicobacter pylori*, 63, 65  
 Helper cells, 3 13, 3 14f  
 Hematopoiesis, 52  
 Hematopoietic stem cells, 40  
 Hematopoietic system, 308  
 Hepatitis B vaccine, 194  
 Hepatitis C virus, 112  
 HHV8, 275  
 HIV-1  
   chemokine receptors and: *see* Chemokine receptors  
   dermatologic disease associated with, 23–24  
   gene therapy and: *see* Gene therapy and HIV-1 infection  
   genomic organization, 240f  
   nucleic acid vaccination against: *see* Nucleic acid vaccination against HIV-1  
   numbers of people infected with, 239  
   passive antibody therapy: *see* Passive immunotherapy against HIV-1  
 HIV-1 accessory genes, 239–267  
 HIV-1 and carbohydrate interactions: *see* Carbohydrate interactions and HIV-1  
 HIV-1 gp41, effects on immune cell function, 41–44  
   humoral responses against, 218–222  
     human monoclonal antibody immunological binding to  
       immunodominant region, 221t  
     human monoclonal anti-HIV-1 antibodies with broad neutralizing activities, 222t  
   peptides, 41–43  
   potential immunomodulating activities, 421  
   synthetic peptide (CS-3), 41–42  
 HIV-1 gp120, effects on immune cell function, 35–41  
   apoptosis, 38  
   carbohydrate interactions, 67–68  
   costimulatory molecules, 39  
   cytokine dysregulation, 39  
   hematopoietic stem cells, 40  
   humoral responses against, 219  
   monocytes, 38  
   potential immunomodulating activities, 36t  
   T cells, 37  
   Th1 and Th2 cytokine profiles, 39–40  
   TNF- $\alpha$ , 40–41  
 HIV-1 life cycle, 288f  
   molecular intervention into, 309f  
 HIV-1 *nef*, effects on immune cell function, 44–53  
   antibodies to *nef*, 45–46  
   CKS-17-related region, 51  
   cytokines, 48–49  
   extracellular role of *nef*, 45–47  
   hematopoiesis, 52  
   MN10042, 51–52  
   myristoylation of N-terminus, 47  
   OKT3 stimulation, 50f  
   peripheral blood cells, *nef*stimulating, 47–48  
   potential immunomodulating activities, 451  
   primate lentiviruses, 48–49  
   soluble *nefn* sera of HIV-1 infected individuals, 49–51  
   synthetic peptides, 49  
   tetanus toxoid, 51, 52f  
 HIV-1 Tat protein  
   immune cell function, effects on, 31–3553  
   potential immunomodulating activities, 32t  
 HIV-2, genomic organization, 240f

- HIV-2, immune responses against, 143–163  
 antibody-dependent cellular cytotoxicity (ADCC), 151–153  
 lymph nodes, 145, 148t  
 B cell epitopes and linear sites, 146–147t, 149–151  
 CD8+ cells, 155–156  
 cell-mediated immunity, 153–156  
 cytotoxic natural killer cells, 156  
 cytotoxic T lymphocyte, 153t, 153–155  
 cytotoxic T lymphocyte peptide epitopes, 153t  
 envelope glycoproteins, cell epitope located in, 146–147t  
 humoral immunity, 145, 148–56  
 large glycoprotein gp125, 149–151  
 responses of different proteins, 144  
 subtypes of HIV-2, 143  
 T helper cells, 156  
 transmembrane protein gp36, 151
- HIV (human immunodeficiency virus), *see also* AIDS (Acquired Immune Deficiency Syndrome)  
 autologous transmission, 7–11  
 environment, 9–11  
 heterologous transmission, differences, 2  
 infectious unit, 7–8  
 target cell, 8–9  
 B cell zone, 10  
 Category A, 1–2  
 Category B, defined, 2  
 Category C, defined, 2  
 CD4+ T lymphocyte, 7, 9  
 cell-free versus cell-associated form, 3  
 heterologous and autologous transmission, differences, 2  
 immunologic dysfunction associated with, 31  
 Langerhans cells, 3–4, 10  
 Mo/Mφ, 3–4  
 mononuclear phagocyte system, 8  
 principle viremia of, 1–16  
 sexual transmission, 3–7  
 antigen-presenting cell population, 3–4  
 antigen-processing cell population, 3  
 cell-free versus cell-associated form, 3  
 environment, 4–7  
 IgA, 5, 6  
 IgM, 5  
 infectious unit, 3  
 major histocompatibility complex (MHC), 4
- HIV (human immunodeficiency virus) (*cont.*)  
 sexual transmission (*cont.*)  
 Mo/Mφ, 3–4  
 mucosa, state of, 5  
 optimum conditions for, 5  
 saliva, 6  
 target cell, 3–4  
 T cell zone, 10
- HIV immune serum globulin, utilization of, 224–225, 226t
- HIV mucosal vaccines, 165–190  
 antigens and routes of immunization, 169t  
 correlates of protection, 168  
 cytotoxic T lymphocytes (CTL), 174, 177  
 DNA vaccines, 180  
 effector sites of mucosal HIV-vaccine induced immune responses, 168f  
 HIV-exposed but uninfected, 168  
 IgA, anti-HIV IgA effector functions 173–174  
 induction of anti-HIV mucosal immune responses, 174–175  
 infection at mucosal surfaces, 166–167  
 live attenuated SIV, 180–181  
 mucosal adjuvants, 181  
 mucosal immune system, organization of, 171  
 need for vaccine, 170–175  
 peptide vaccines, 177–178  
 potential mechanisms of HIV transmission, 167f  
 protein subunits, 175–176  
 recombinant bacterial vectors, 179–180  
 recombinant viral vectors, 179  
 secretory-IgA, 172–174  
 strategies, 175–181  
 virus-like particles, 178–179
- HIV RNA, monitoring in children, 339–340
- HLA: *see* Human leukocyte antigen (HLA)
- HTLV (human T-cell leukemia/lymphoma viruses)  
 dermatologic disease, 23–24  
 diseases other than ATL, role in, 17–28  
 autoimmune diseases, 22–23  
 chronic fatigue syndrome, 24  
 inflammatory diseases, 22–23  
 neurological disease, 18–20  
 thyroid, serologic abnormalities of, 23  
*env* gene, 89  
 hematologic disease, 20–22  
 HTLV genome, 89f

- HTLV (human T-cell leukemia/lymphoma viruses) (*cont.*)
- HTLV-I: *see* HTLV-I
  - HTLV-II: *see* HTLV-II
  - myasthenia gravis and, 20
  - passive immunotherapy, 217–218
  - vaccine development, 91–93
- HTLV-I
- adhesion molecules and HTLV infection, 95–103
    - three possible roles, 103f
  - autoimmune diseases associated with, 22–23
  - biology of HTLV, 88–91
  - chronic fatigue syndrome associated with, 24
  - cutaneous T-cell lymphoma (CTCL) and, 21
  - disease associations of, 18f
  - HAM: *see* HAM (HTLV-I associated myelopathy)
  - hematologic disease associated with, 20–22
  - identification of, 17
  - immunological and molecular aspects, 87–107
  - inflammatory diseases associated with, 22–23
  - neurologic disease associated with, 18–20
  - numbers of people infected with, 91
  - receptors for, 93–95
  - syncytia, cells having ability to form with infected MT2 cells, 94f
  - transmission of, 110
  - vaccine development, 91–93, 109–142
    - animal models, 113–116
    - animal vaccine challenge studies, 125f; 125–129
    - approaches, 117–120, 118f
    - candidates for vaccine, 120–125
    - DNA gene transfer, immunization by, 119–120
    - envelope glycoprotein, 122–123
    - feasibility of generating, 112
    - gag*, 123–124
    - genetic stability and, 112–113
    - HTLV-I tropism, 111
    - inactivated attenuated viruses, 117
    - issues relevant, 111–113
    - live attenuated viruses, 117
    - live vectors, 118–119
- HTLV-I (*cont.*)
- vaccine development (*cont.*)
    - modes of challenge, 116
    - natural immune response, 112
    - nonhuman primate vaccine studies, 129
    - pol* and pX region proteins, 121
    - polyvalent vaccine, 124–125
    - rabbit vaccine studies, 126–128
    - rat vaccine studies, 125–126
    - subunit approach, 118
    - tax protein, 121
- HTLV-I associated myelopathy: *see* HAM (HTLV-I associated myelopathy)
- HTLV-II
- adhesion molecules and HTLV infection, 95–103
  - biology of HTLV, 88–91
  - chronic fatigue syndrome associated with, 24
  - cutaneous T-cell lymphoma (CTCL) and, 21
  - dermatologic disease associated with, 23–24
  - disease associations of, 19f
  - gait and bladder dysfunction associated with, 19
  - hematologic disease associated with, 20–22
  - immunological and molecular aspects, 87–107
  - inflammatory diseases associated with, 23
  - isolation of, 18
  - neurologic disease associated with, 19–20
  - receptors for, 93–95
- Human chromosomes, HTLV infection, 99
- Human immunodeficiency virus (HIV): *see* HIV (human immunodeficiency virus)
- Human leukocyte antigen (HLA), 154, 312
- Human studies
- nucleic acid vaccination against HIV-1, 208–210
  - passive immunotherapy against HIV-1, 227, 229
- Human T-cell leukemia/lymphoma viruses (HTLV): *see* HTLV (human T-cell leukemia/lymphoma viruses)
- Human T-lymphotropic virus type I (HTLV I): *see* HTLV-I

- Humoral responses  
 HIV-2, immune responses against, 145, 148–156  
 nucleic acid vaccination against HIV-1, 194–195  
 passive immunotherapy against HIV-1  
 gp41, responses against, 218–222  
 gp120, responses against, 219  
 HIV-1, responses against, 218  
 protective efficacy of humoral immunity, 223–224  
 Hu-PBL-SCID mouse model, 229–230, 231t  
 Hypercalcemia, 21
- ICAM-1, 98, 102  
 ICAM-2, 102  
 ICAM-3, 96–99, 100–101f, 102  
 Ichthyosis, 23  
 IgA  
 carbohydrate interactions and HIV-1, 78–79  
 HIV mucosal vaccines, 172–174  
 anti-HIV IgA effector functions, 173–174  
 sexual transmission of HIV, 5, 6  
 IgM, 5  
 IL-10 mRNA, 44  
 Immunological monitoring in children, 338–339  
 Immunostimulatory sequences, nucleic acid vaccination against HIV-1, 205  
 Inactivated attenuated viruses, vaccine development, 117  
 Indinavir, 293, 295, 296f, 336, 341  
 Infants, HIV diagnosis, 338  
 Inflammatory diseases, HTLV-associated, 22–23  
 Influenza vaccine, 195
- Joint United Nations Programme on HIV/AIDS, 239
- Kieber-Emmons, Thomas, 61–85  
 Kudchodkar, Sagar, 239–267
- LAK cells: *see* Lymphokine-activated killer (LAK) cells  
 Lamivudine, 332  
 Langerhans cells, 3–4, 10  
 Leukemia  
 ATL (adult T cell leukemia), 87  
 HTLV: *see* HTLV (human T-cell leukemia/lymphoma viruses)
- LeY antigen, 66  
 LeY is, 66–67  
 LFA-1, 98  
*Limulus polyphemus*, 277  
 Live attenuated SIV, 180–181  
 Live attenuated viruses, vaccine development, 117  
 Live vectors, vaccine development, 118–119  
 Los Alamos National Laboratory, 273  
 Loughran, Thomas P., 17–28  
 Lymphokine-activated killer (LAK) cells, 43  
 Lytic bone lesions, 21
- Major histocompatibility class (MHC) class II antigens, 91  
 McGhee, Jerry R., 165–190  
 Measles vaccination, 191, 241  
 MN10042, 51–52  
 Mo/Mφ  
 autologous transmission, 7–11  
 sexual transmission, 3–4  
 Monoclonal antibodies, passive immunotherapy against HIV-1, 225, 227–230  
 chimpanzee model, 225, 227, 228t  
 human monoclonal antibody immunological binding to immunodominant region, 221t  
 human monoclonal anti-HIV-1 antibodies with broad neutralizing activities, 222t  
 human trials, 227, 229  
 Hu-PBL-SCID mouse model, 229–230, 231t
- Monocytes, effects of HIV-1 gp120, 38  
 Mononuclear phagocyte system, 8  
 M-tropic viruses, 271, 278  
 Mucosal adjuvants, 181  
 Mucosal-associated lymphoreticular tissue (MALT), 6  
 Mucosal immune responses, carbohydrate interactions and HIV-1, 78–79  
 Mucosal vaccines: *see* HIV mucosal vaccines  
 Murine leukemia virus (MLV), 314–316  
 Murine studies: *see* Nucleic acid vaccination against HIV-1  
 Myasthenia gravis, 20
- Nagashunmugam, T., 239–267  
 Naked DNA, 313

- Nasal-associated lymphoreticular tissue (NALT), 6
- National Pediatric and Family HIV Resource Center (NPHRC), 328  
principles enunciated by, 329–330
- Natural killer cells, 156
- Nef* gene, *see also* HIV-1 *nef*, effects on immune cell function  
CD4, interaction, 251  
nucleic acid vaccination against HIV-1, 197–198  
simian immunodeficiency virus (SIV), 45, 198, 250  
structure and function, 250–252  
vaccine and drug studies, 252–253  
viral replication, 252f
- Neisseria*, 63, 65  
*Neisseria gonorrhoeae*, 64, 65  
*Neisseria meningitidis*, 63, 64, 75
- Nelfinavir, 293–294, 336–337, 341
- Nelson, Robert P., Jr., 325–356
- Neurological disease, HTLV-I and -II, 18–20
- Nevirapine, 334
- NNRTIs: *see* Nonnucleoside reverse transcriptase inhibitors (NNRTIs)
- Nonhuman primate models, vaccine development, 115–116
- Nonhuman primate vaccine studies, 129
- Nonnucleoside reverse transcriptase inhibitors (NNRTIs), 331, 334–335  
delavirdine, 335  
efavirenz, 334–335  
nevirapine, 334
- NPHRC: *see* National Pediatric and Family HIV Resource Center (NPHRC)
- NRTIs: *see* Nucleoside reverse transcriptase inhibitors (NRTIs)
- Nucleic acid vaccination against HIV-1, 191–215  
accessory genes, 197–198  
advantages of, 199–200, 200t  
CD4 cells, 203–204  
cellular responses, 195–196  
cytokines, 203–204  
cytotoxic T lymphocytes (CTL), 195  
DNA vaccination, 197f, 199–200, 209t  
*gag/pol* genes, 198, 209–210  
genome of HIV-1, 196–199  
human studies, 208–210  
humoral responses, 194–195
- Nucleic acid vaccination against HIV-1  
(*cont.*)  
murine studies, 200–206  
codon optimization, 205–206  
CpG motifs, 205  
immune responses, 200–202  
immunostimulatory sequences, 205  
modulation of immune response, 203–204  
mucosal immunity, studies of, 202–203  
*nef*, 197–198  
obstacles to development, 192–196  
primate studies, 206–208  
progress of nucleic acid immunization, 200–210  
proposed mechanism, 193f  
RANTES, 196  
*rev* regulatory gene, 196–197, 209  
strategies, 192t, 193f  
*tat* regulatory gene, 196–197  
T helper cells, 195  
*vif* gene, 197–198  
*vpr*, 197–198  
*vpu*, 197–198
- Nucleoside analogue reverse transcriptase inhibitors: *see* Nucleoside reverse transcriptase inhibitors (NRTIs)
- Nucleoside reverse transcriptase inhibitors (NRTIs), 331–334  
abacavir sulfate, 333  
combination nucleoside therapies, 333–334  
dideoxyinosine (Didanosine), 331–332  
lamivudine, 332  
stavudine, 332  
zalcitabine, 332  
zidovudine (Azidothymidine), 331
- Nucleotide reverse transcriptase inhibitors, adefovir dipivoxil, 337
- Office of AIDS Research, NIH, 326–328
- Oligonucleotides, 205
- Oncovirinae subfamily of retroviruses, 88
- Pancytopenia, 21–22
- Passive immunotherapy against HIV-1, 217–238  
convergent/synergistic passive immunotherapy, 222–223  
feline immunodeficiency virus (FIV), 217  
HIV immune serum globulin, utilization of, 224–225, 226t



- Passive immunotherapy against HIV-1 (*cont.*)
- humoral responses
    - gp41, against, 218–222
    - gp120, against, 219
    - HIV-1, against, 218
    - protective efficacy of humoral immunity, 223–224
  - monoclonal antibodies utilized, 225: 227–230
    - chimpanzee model, 225,227,228t
    - human monoclonal antibody immunological binding to immunodominant region, 221t
    - human monoclonal anti-HIV-1 antibodies with broad neutralizing activities, 222t
    - human trials, 227, 229
    - Hu-PBL-SCID mouse model, 229–230, 231t
    - simian immunodeficiency virus (SIV), 217
- PBMCs: *see* Peripheral blood mononuclear cells (PBMCs)
- Pediatric AIDS Clinical Trials Group (PACTG), 333–334
- Pediatric HIV
- antiretroviral therapy, 325–356
    - abacavir sulfate, 333
    - adherence, factors influencing, 342t
    - antiretroviral agents, 331–337
    - changes in therapy, 341–342
    - choice of therapy, 341
    - classification system, 339f
    - combination nucleoside therapies, 333–334
    - currently available drugs, characteristics of, 344–353
    - delavirdine, 335
    - dideoxyinosine (Didanosine), 331–332
    - duration of therapy, 342
    - efavirenz, 334–335
    - HIV RNA, monitoring in children, 339–340
    - identification of perinatal HIV exposure, 337–338
    - immunological monitoring in children, 338–339
    - indinaver, 336, 341
    - infants, HIV diagnosis, 338
    - initiation of therapy, 340
    - lamivudine, 332
    - nelfinavir, 336–337, 341
  - Pediatric HIV (*cont.*)
    - antiretroviral therapy (*cont.*)
      - nevirapine, 334
      - nonnucleoside reverse transcriptase inhibitors (NNRTIs), 331, 334–335
      - nucleoside reverse transcriptase inhibitors (NRTIs), 331
      - nucleotide reverse transcriptase inhibitor, 337
    - Office of AIDS Research, principles of therapies, 326–328
    - protease inhibitors, 335–337
    - ritonavir, 335–336
    - salvage antiretroviral therapy, 343
    - stavudine, 332
    - treatment, 337–343
    - Working Group of NPHRC, principles enunciated by, 329–330
    - zalcitabine, 332
    - zidovudine, 331
  - antiviral drug therapies, 287–295
    - classification system, 339f
    - currently available drugs, characteristics of, 344–353
  - HIV-infected women, identification of, 328–329
  - indinavir, 293, 295, 296f, 336, 341
  - nelfinavir, 293–294, 336–337, 341
  - obstetric factors, 325–326
  - protease inhibitors and HIV-1 genetic variability
    - amino acid substitutions, summary, 298f
    - amino acid polymorphisms, 290f
    - antiviral drug therapies, 287–295
    - baseline, genetic changes in env relative to, 300–302
    - change in PR alleles during therapy, 299f
    - clinical response, 292–294
    - env region of virus genome, variability, 300–303
    - evolution of virus with inhibitor, 298–300
    - genetic analysis, 295–300
    - genetic analysis and reservoirs of viruses, 303
    - genetic cell analysis, 295–300
    - genotypic resistance in protease, 297, 298f
  - HIV-1 genetic variability and, 287–305
  - HIV-1 genome, 289f

- Pediatric HIV (*cont.*)  
 protease inhibitors and HIV-1 genetic variability(*cont.*)  
 HIV-1 life cycle, 288f  
 HIV-1 protease, 288–289  
 HIV-1 targets for drugs, 288  
 immune reconstitution following, 294–295  
 models for emergence of virus, 300f  
 phylogenetic trees, 296–297, 302  
 V3 amino acids, changes in, 300–302  
 viral drug resistance, 289–291  
 ritonavir, 292–295, 296f, 335–336  
 salvage antiretroviral therapy, 343  
 Peptide vaccines, 177–178  
 Perez, Elena E., 287–305  
 Perinatal HIV exposure, identification of, 337–338  
 Peripheral blood leukocytosis, 2 1  
 tetanus toxoid-stimulated proliferation of, 51  
 Peripheral blood mononuclear cells (PBMCs), 31–32, 44  
 Pertussis toxin (PT), 181  
 Peters, A., 109–142  
 Phylogenetic trees, 296–297, 302  
 Plasmid DNA inoculation, 92  
 Pol and pX region proteins, 121  
 Polgene, 144  
 Polio vaccination, 191  
 Polyvalent vaccine, 124–125  
 Pomerantz, Roger, 307–323  
 Principal neutralizing domain (PND), 149  
 PR inhibitors: *see* Pediatric HIV  
 Polymphocytic leukemia, 21  
 Prostatomes, 6  
 Protease inhibitors, pediatric HIV  
 antiretroviral therapy, 335–337  
 indinaver, 336, 341  
 nelfinavir, 336–337, 341  
 nucleotide reverse transcriptase inhibitor, 337  
 ritonavir, 335–336  
 HIV-1 genetic variability, 287–305  
 amino acid substitutions, summary, 298f  
 amino acid polymorphisms, 290f  
 antiviral drug therapies, 287–295  
 baseline, genetic changes in *env* relative to, 300–302  
 change in PR alleles during therapy, 299f  
 Protease inhibitors, pediatric HIV (*cont.*)  
 HIV-1 genetic variability (*cont.*)  
 clinical response, 292–294  
*env* region of virus genome, variability, 300–303  
 evolution of virus with inhibitor, 298–300  
 genetic analysis, 295–300  
 genetic analysis and reservoirs of viruses, 303  
 genetic cell analysis, 295–300  
 genotypic resistance in protease, 297, 298f  
 HIV-1 genome, 289f  
 HIV-1 life cycle, 288f  
 HIV-1 protease, 288–289  
 HIV-1 targets for drugs, 288  
 immune reconstitution following, 294–295  
 models for emergence of virus, 300f  
 phylogenetic trees, 296–297, 302  
 V3 amino acids, changes in, 300–302  
 viral drug resistance, 289–291  
 Pure red cell aplasia, 22  
 Rabbit vaccine studies, 126–128  
 Rabies vaccine, 194  
 RANTES  
 chemokine receptors, therapeutics directed at, 275  
 nucleic acid vaccination against HIV-1, 196  
 Rational drug design techniques, 257  
 Rat vaccine studies, 125–126  
 Recombinant bacterial vectors, 179–180  
 Recombinant vesicular stomatitis virus (VSV), 316  
 Recombinant viral vectors, 179  
 Retroviral packaging cells, 314f  
 Reverse transcriptase, 240  
 Reverse transcriptase (RT) inhibitors, 287  
 Rev regulatory gene  
 DNA decoys, 310  
 nucleic acid vaccination against HIV-1, 196–197, 209  
 Rev-response element, 197  
 Rex gene, 91  
 Ribozymes, 308–310  
 Ritonavir, 292–295, 296f, 335–336  
 RNA, 240  
 antisense RNAs, 308–310  
 HIV RNA, monitoring in children, 339–340

- Rodent models, vaccine development, 113–115
- Saccharomyces cerevisiae*, 66
- SAIDS retrovirus, 113
- Saliva, transmission of HIV, 6
- Salmonella*, 118, 180
- Saquinavir, 341
- Secretory-IgA, HIV mucosal vaccines, 172–174
- Sexual transmission of HIV, 3–7  
 antigen-presenting cell population, 3–4  
 cell-free versus cell-associated form, 3  
 environment, 4–7  
 IgA, 5, 6  
 IgM, 5  
 infectious unit, 3  
 major histocompatibility complex (MHC), 4  
 Mo/M $\phi$ , 3–4  
 mucosa, state of, 5  
 optimum conditions for, 5  
 saliva, 65  
 target cell, 3–4
- Shah, Ami R., 191–215
- SHIV: *see* Chimeric simian/immunodeficiency virus (SHIV)
- S-IgA: *see* Secretory-IgA
- Simian immunodeficiency virus (SIV), 5, 29  
 cytotoxic T lymphocyte, 155  
 genomic organization, 240f  
 mucosal vaccine development and, 166–167, 170, 176  
 live attenuated SIV, 180–181  
*nefgene*, 45, 198, 250  
 passive immunotherapy against HIV-1, 217  
*vpxgene*, 240
- Single-chain antibodies, 312
- Single-strand DNA, 313
- SIV: *see* Simian immunodeficiency virus (SIV)
- 6F9, 75
- Sjogren's syndrome, 22–23
- Sleasman, John W., 287–305
- Small-molecule inhibitors of chemokine receptors, 276–279
- Smallpox vaccination, 241
- Southwest Foundation (New Mexico), 116
- Specialized gut-associated lymphoreticular tissue (GALT), 6
- Staats, Herman F., 165–190
- Stavudine, 332
- Stem cell inhibitor, 275
- Subunit approach, vaccine development, 118
- Sustiva, 334–335
- Synthetic peptides, 123
- T22, 277
- TAR: *see* Tat-response (TAR) element
- Targeted iliac lymph node (TILN), 170, 176
- Tat  
 DNA decoys, 310  
 nucleic acid vaccination against HIV-1, 196–197  
 virion formation, 240–241
- Tat-response (TAR) element, 31; *see also* HIV-1 Tat
- Tax* gene, 90–91
- Tax proteins, 22, 24  
 binding to CREB, CREM, 90f  
 nuclear factor, activation, 90  
 vaccine development, 121
- T cells  
 carbohydrate antigens, 74–75  
 immunosuppressive effects on, 34  
 HIV-1 gp120, 37  
 HIV-1 *nef*, 48
- TCID<sub>50</sub>, 2
- Tetanus toxoid, 51, 52f
- Tetanus toxoid-stimulated proliferation of PBMCs, 51
- Tetanus vaccination, 191
- Th1 and Th2 cytokine profiles HIV-1 gp120, effects of, 39–40
- T helper cells, 239  
 HIV-1 gp120, effects of, 37  
 HIV-2, immune responses against, 156  
 HIV mucosal vaccines, 177–178  
 HTLV vaccine development and, 92  
 nucleic acid vaccination against HIV-1, 195
- T helper lymphocyte function, loss of, 31
- Thrombotic microangiopathy, 22
- Thyroid, serologic abnormalities of associated with HTLV, 23
- TNF- $\alpha$ , HIV-1 gp120, effects of, 40–41
- Toxic genes, 311–312
- Transdominant mutant proteins, 310–311
- T-tropic viruses, 270, 271f, 278
- Tuberculosis vaccination, 191

- Ugen, Kenneth E., 217–238
- United Nations Joint Programme on AIDS, 191
- US. Public Health Service, 338
- V3, nucleotide distances during therapy with PR inhibitors, 300–302
- V3, role of glycans, 69–71
- V3 amino acids, 302–303
- Vaccine and drug studies  
*nef*, 252–253  
*vif*, 245  
*vpr*, 255–256  
*vpu*, 249
- Vaccine development  
 animal models  
   nonhuman primate models, 115–116  
   rodent models, 113–115  
 carbohydrates and, 62–63, 72–77  
   peptide motifs that mimic carbohydrate structures, 76t  
   planar-X-planar sequence motif, 76  
   T lymphotropic virus type I, 72–73  
 HIV mucosal vaccines, 165–190; *see also* HIV mucosal vaccines  
 HTLV-I, 91–93, 109–142  
   animal models, 113–116  
   animal vaccine challenge studies, 125f, 125–129, 130  
   approaches, 117–120, 118f  
   candidates for vaccine, 120–125  
   DNA gene transfer, immunization by, 119–120  
   envelope glycoprotein, 122–123  
   feasibility of generating, 112  
   *gag*, 123–124  
   genetic stability and, 112–113  
   HTLV-I tropism, 111  
   inactivated attenuated viruses, 117  
   issues relevant, 111–113  
   live attenuated viruses, 117  
   live vectors, 118–119  
   modes of challenge, 116  
   natural immune response, 112  
   nonhuman primate vaccine studies, 129  
   *pol* and pX region proteins, 121  
   polyvalent vaccine, 124–125  
   rabbit vaccine studies, 126–128
- Vaccine development (*cont.*)  
 HTLV-I (*cont.*)  
   srat vaccine studies, 125–126  
   ubunit approach, 118  
   tax protein, 121  
   nonhuman primate models, 115–116  
   nucleic acid vaccination against HIV-1: *see* Nucleic acid vaccination against HIV-1  
*Vif* gene, 197–198, 242–247  
   clinical isolate, 247f  
   comparison of *vif* induced amino acid sequences, 246f  
   structure and function, 242–245  
   subcellular localization, 243f  
   vaccine and drug studies, 245  
 Viracept, 336–337, 341  
 Viral infectivity factor: *see* *Vif* gene  
 Viral protein R: *see* *Vpr*  
 Viral protein U: *see* *Vpu*  
 Virion formation, 240–241  
 Virus-like particles, HIV mucosal vaccines, 178–179  
*Vpr*, 197–198  
   cell proliferation effect on, 255f  
   G<sub>2M</sub> accumulation of cells, 256f  
   structure and function, 253–255  
   vaccine and drug studies, 255–256  
*Vpu*, 197–198  
   structure and function, 247–249  
   vaccine and drug studies, 249  
*Vpx* gene, simian immunodeficiency virus (SIV), 240
- Weiner, David B., 191–215
- Whooping cough vaccination, 191
- Working Group on Antiretroviral Therapy and Medical Management of HIV Infection Children, 328  
   principles enunciated by, 329–330
- World Health Organization, 191
- X-ray crystallography, 257
- YYPYD, 76–77  
 YYRYD, 75–77
- Zalcitabine, 332
- Zidovudine, 287, 331, 341